2048 Ventures

2048 Ventures is an earliest-stage firm operating between New York and Boston, with a portfolio thesis that spans vertical AI, deep tech, healthcare, and biotech. The firm is on its third fund at roughly eighty-two million dollars in committed capital, which places it in the institutional but still founder-friendly tier of pre-seed and seed funds. The capital base is large enough to write conviction-sized first checks but small enough that the partnership can move quickly and remain deeply involved with each portfolio company. For healthcare and biotech founders raising at pre-seed or seed in the Northeast corridor, 2048 represents the kind of fund that can lead a first priced round, anchor a syndicate, and provide meaningful runway without yet bringing the structural overhead of a larger Series A institutional investor.

The stated thesis spans four overlapping interest areas: vertical AI, deep tech, healthcare, and biotech. What unifies them is the firm’s preference for technical founders building defensible products at the earliest stage, where the bet is on the team and the technology rather than on commercial traction. In healthcare, the implications are specific. The firm is not a generalist digital health investor chasing direct-to-consumer wellness or telehealth commodities; it is looking for AI-native healthcare platforms, for biotech infrastructure plays, and for vertical AI companies that happen to address healthcare workflows. The AI focus is genuine and central, with the firm explicit that vertical AI is one of its core thesis areas. Founders should expect diligence to dig into technical depth, into the founders’ background in machine learning or applied science, and into whether the company’s moat compounds with data over time. Companies whose AI is decorative rather than structural will not survive the conversation. The bias toward deep tech and biotech also means the firm is comfortable with longer commercialization timelines than a pure SaaS investor, which is meaningful for healthcare founders facing regulatory or clinical-validation pathways.

This profile does not include a specific list of portfolio companies. Founders should consult the 2048 Ventures portfolio page and study which healthcare and biotech investments have progressed to Series A and beyond inside the portfolio versus which have stalled. The progression pattern reveals which subsectors the partnership has built genuine conviction in. Founders should also identify which investments have attracted follow-on capital from major Series A healthcare specialists, because the lead-syndicate quality of those follow-ons is a strong signal about how the broader market views companies that 2048 backed early.

The two hundred fifty thousand to one million dollar check size range, with the firm’s earliest-stage positioning, places 2048 as a pre-seed and seed lead or co-lead. The check is small enough to fit cleanly into a syndicated pre-seed round and large enough to anchor a seed round when 2048 is the institutional lead. Founders should plan their cap table assuming 2048 will not lead the Series A, but will participate in pro-rata to the extent reserves permit. The firm’s third-fund size of roughly eighty-two million dollars implies meaningful but not unlimited reserves, which means follow-on participation will be selective rather than automatic. The firm syndicates with other Northeast pre-seed and seed funds, with sector-specialist healthcare and biotech early-stage investors, and increasingly with West Coast deep-tech funds drawn into AI-native deals.

Team member names are not enumerated in the source data for this profile. Founders should consult the firm’s website and LinkedIn presence to identify current investing partners and pay particular attention to which have technical or operating backgrounds in healthcare, biotech, or applied AI. Decision-making at a fund of this size is typically led by a sponsoring partner with partnership-level review, and the cycle from first meeting to term sheet is generally faster than at larger institutional funds.

The most reliable path into 2048 Ventures is a warm introduction from a portfolio founder, from a co-investor at the pre-seed and seed stage, or from a faculty connection at a Northeast research university. The firm’s New York and Boston positioning means the academic and operator networks of those two cities are central to deal flow. Cold inbound through the firm’s website is read, particularly when the founder can articulate technical depth in the first message and when the company sits clearly inside one of the firm’s stated thesis areas. Communication should be technical, brief, and grounded in what the company actually does rather than in narrative around the market.

Founders should approach 2048 Ventures when they are at pre-seed or seed, when the founding team has technical depth in AI, healthcare, or biotech, and when the company is building something with real defensibility rather than a wrapper on a foundation model. The firm is not the right fit for consumer digital health without an AI substrate, for late-seed rounds raising more than four million dollars, or for non-technical founding teams in deep-tech-adjacent spaces. It is an excellent fit for AI-native healthcare infrastructure, for biotech tooling and computational biology platforms, and for vertical AI companies addressing specific healthcare workflows. The earliest-stage positioning means founders get the firm’s attention at the moment when small checks have the most impact on company-building.